Literature DB >> 19548312

Sox17-2A-iCre: a knock-in mouse line expressing Cre recombinase in endoderm and vascular endothelial cells.

Silvia Engert1, W Perry Liao, Ingo Burtscher, Heiko Lickert.   

Abstract

Sox17 encodes an SRY-related high-mobility group (HMG) box transcription factor that is essential for endoderm formation and fetal hematopoietic stem cell maintenance. In the mouse, expression of Sox17 is first observed in the extraembryonic endoderm and is subsequently seen in the definitive endoderm as well as in blood and the endothelial cells of the developing vasculature. To conditionally inactivate genes in these domains, we have targeted the Sox17 locus to generate a bicistronic mRNA linking Sox17 to a codon improved Cre recombinase (iCre) via a viral 2A sequence. Here we report a new Cre knock-in mouse line, Sox17-2A-iCre, with activity in the developing endoderm, the vascular endothelial cells of the cardiovascular system and the hematopoietic system. Our results indicate that the Sox17-2A-iCre is active in an early endoderm progenitor and recombination of the Rosa26 reporter was observed in all previously reported expression domains of Sox17. The Sox17-2A-iCre line will be an excellent tool to conditionally inactivate genes in the definitive endoderm as well as in the vasculature and hematopoietic system. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19548312     DOI: 10.1002/dvg.20540

Source DB:  PubMed          Journal:  Genesis        ISSN: 1526-954X            Impact factor:   2.487


  32 in total

1.  Return to youth with Sox17.

Authors:  Akanksha Chhabra; Hanna K A Mikkola
Journal:  Genes Dev       Date:  2011-08-01       Impact factor: 11.361

2.  Dominant and context-specific control of endodermal organ allocation by Ptf1a.

Authors:  Spencer G Willet; Michael A Hale; Anne Grapin-Botton; Mark A Magnuson; Raymond J MacDonald; Christopher V E Wright
Journal:  Development       Date:  2014-11       Impact factor: 6.868

3.  Sox17 is required for normal pulmonary vascular morphogenesis.

Authors:  Alexander W Lange; Hans Michael Haitchi; Timothy D LeCras; Anusha Sridharan; Yan Xu; Susan E Wert; Jeanne James; Nicholas Udell; Philipp J Thurner; Jeffrey A Whitsett
Journal:  Dev Biol       Date:  2014-01-10       Impact factor: 3.582

Review 4.  Pancreas-specific Cre driver lines and considerations for their prudent use.

Authors:  Mark A Magnuson; Anna B Osipovich
Journal:  Cell Metab       Date:  2013-07-02       Impact factor: 27.287

5.  Wntless is required for peripheral lung differentiation and pulmonary vascular development.

Authors:  Bridget Cornett; John Snowball; Brian M Varisco; Richard Lang; Jeffrey Whitsett; Debora Sinner
Journal:  Dev Biol       Date:  2013-03-21       Impact factor: 3.582

Review 6.  On the Origin of Cells and Derivation of Thyroid Cancer: C Cell Story Revisited.

Authors:  Mikael Nilsson; Dillwyn Williams
Journal:  Eur Thyroid J       Date:  2016-06-24

7.  Localised inhibition of FGF signalling in the third pharyngeal pouch is required for normal thymus and parathyroid organogenesis.

Authors:  Jennifer R Gardiner; Abigail L Jackson; Julie Gordon; Heiko Lickert; Nancy R Manley; M Albert Basson
Journal:  Development       Date:  2012-09       Impact factor: 6.868

8.  Dual lineage-specific expression of Sox17 during mouse embryogenesis.

Authors:  Eunyoung Choi; Marine R C Kraus; Laurence A Lemaire; Momoko Yoshimoto; Sasidhar Vemula; Leah A Potter; Elisabetta Manduchi; Christian J Stoeckert; Anne Grapin-Botton; Mark A Magnuson
Journal:  Stem Cells       Date:  2012-10       Impact factor: 6.277

9.  Targeting SOX17 in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm.

Authors:  Pei Wang; Ryan T Rodriguez; Jing Wang; Amar Ghodasara; Seung K Kim
Journal:  Cell Stem Cell       Date:  2011-03-04       Impact factor: 24.633

Review 10.  Endothelial-Specific Cre Mouse Models.

Authors:  Sophie Payne; Sarah De Val; Alice Neal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.